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Introduction
The properdin (P)' system, also known as the alternative complement pathway, was originally characterized as a system of natural immunity which did not require antibody and which 1. Abbreviations used in this paper: ARDS, adult respiratory distress syndrome; Bb, proteolytic fragment of complement Factor B; C3, third component of complement; C3b, major cleavage fragment ofC3; C3NeF, C3 nephritic factor; C5, fifth component of complement; ER, rabbit functioned in host defense against various pathogens including bacteria, viruses, and protozoa (1) . The alternative complement pathway has been implicated in the pathogenesis or symptomatology of a broad spectrum of human diseases and pathologic conditions. These include: infections with gram-positive and gram-negative bacteria (2, 3) , viruses (4, 5) , parasites (6, 7) , and fungi (8) ; various dermatologic (9) , renal (10) , and hematologic (11) (12) (13) diseases; adult respiratory distress syndrome (ARDS) associated with gram-negative septicemia, trauma, and burns (14) (15) (16) (17) (18) ; contact with dialysis membranes such as in hemodialysis (19) and cardiac bypass surgery (20) ; and miscellaneous conditions (21). In vitro studies indicate that a number of gramnegative bacteria and bacterial products (22) , virus-infected cells (23) , viruses (24) , protozoa (25) , fungi (26) , burned, damaged, and injured cells (27) , and other substances of biomedical importance (28) have the ability to activate the alternative pathway in human serum.
Multiple studies during the past few years have identified the components of the alternative complement pathway and have elucidated their reaction mechanisms (29, 30) . Activation of this pathway leads to the assembly of a multicomponent enzyme on the surface of the activator. This enzyme, third component of complement (C3b), proteolytic fragment of complement Factor B (Bb), P, is able to cleave fifth component of complement (CS) and initiate the membranolytic portion of the complement reaction sequence. The methods presently available to assess and quantitate alternative pathway function and activation are limited in number and utility and most are available only in laboratories engaged in research on the alternative pathway.
This paper describes an enzyme-linked immunosorbent assay (ELISA) which can quantitate the C3b,Bb,P complex or its derivative product, C3b,P on the surface of activators or in serum or plasma. This method thus directly measures activation of the alternative complement pathway. In addition to absolute specificity, the ELISA is extremely sensitive and capable of quantitating specific activation of 0.0015% of the C3 in plasma.
The studies presented here not only validate the ELISA and quantitate its parameters, but also illustrate its utility for detailed analysis of activation of the alternative pathway by isolated viruses, virus-infected cells, and bacteria. In addition, moderate to marked ELISA reactivity was observed in sera from those patients with diseases in which alternative pathway activation would be expected.
Methods
Reagents and buffers. Tween (37) , Clq, and nephritic factor (C3NeF) (38, 39) were prepared or purified as described in References. P was purified by a modification of the method of Medicus et al. (40) . Briefly, EDTA was added to normal serum to a concentration of 5 mM and the serum was passed over BioRex 70 (Bio-Rad Laboratories, Rich- mond, CA), as previously described for Clq purification (38) . Fall-through fractions containing P were pooled and dialyzed into 20 mM Tris-HCI containing 30 mM NaCl, pH 8.5, K = 3.9. The remainder ofthe procedure was as published (40) . Activated P was generated by repetitive freezethawing of the preparation (40 The cells were harvested at a concentration of 1 X 106/ml, washed two times in PBS, and viability was ascertained to be >95% by trypan blue exclusion before use.
Gram-negative bacteria included serum sensitive Escherichia coli 04 and serum resistant Klebsiella pneumonia laboratory strains. The bacteria were grown in trypticase soy broth (Becton-Dixon Co., Cockeysville, MD) and harvested at a concentration of I X 109/ml, as determined by nephelometry and colony-forming unit determination. The organisms were washed three times in VBS++ and heat killed for I h at 80'C before use.
Zymosan A (Sigma Chemical Co.) was boiled for 2 h in 0.15 M NaCl. The particles were washed in VBS++ and resuspended to -50 mg/ml and frozen at -70'C in aliquots until use.
Human tetanus-antitetanus immune complexes were generated as previously described (43 Affinity purification ofanti-C3 and anti-Pfor use in the ELISA. 10 mg of C3 and 1 mg of P were separately coupled to 1 g of CNBractivated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) using the instructions of the manufacturer. Monospecific goat anti-C3 and rabbit anti-P sera were precipitated with 33% ammonium sulfate. The precipitates, after dissolution and dialysis into VBS, were passed through the appropriate C3 or P columns in VBS. After extensive washing with 3 M NaCI in VBS, the columns were stripped with 0.2 M glycine-HCI, pH 2.2. The protein-containing fractions were pooled, immediately neutralized, and dialyzed into PBS. The affinity-purified antibodies were frozen at -70'C until use. Alkaline phosphatase-labeling ofantibodies. Alkaline phosphatase (Sigma type VII) was conjugated to the above described, affinity-purified anti-C3 by the method of Voller (48) . The dilution of the enzymelabeled antibody to C3 to be used was determined by adding 1:100 to 1:5,000 dilutions to wells ofa microtitration plate (Linbro Sterile/Titertek, Linbro Chemical Co., Hamden, CT) previously coated with affinitypurified IgG antibody to C3 (5 gg/ml) followed by a 1:10,000 dilution ofserum (see below). The ELISA was then performed as described below and the highest conjugate dilution that gives an optical density reading ofjust under 2.0 at 405 nm was determined. This dilution was generally 1:750.
ELISA. The assay was a modification of the standard method of Voller (48) . Microtitration plates were coated with 0.1 ml volumes of the affinity-purified anti-P antibody at a concentration of 5 j&g/ml in PBS by overnight dessication at room temperature. Next, 0.2 ml of PBS:0.5% BSA were added and the plates incubated for 2 h at 370C in a humid incubator. After removal of this blocking solution, the plates were washed once with PBS containing 0.05% Tween 20 (PBS-Tween).
Dilutions ofsamples to be tested for ELISA reactivity in PBS-Tween-10 mM EDTA-0.25% BSA (PBS-Tween-EDTA-BSA) were placed in 0.1 ml volumes, in triplicate, into the coated plates. After rocking for 1 h at room temperature, the plates were washed three times with PBSTween. Next, 0.1 ml of alkaline phosphatase-conjugated antibody to C3 diluted in PBS-Tween-EDTA-BSA was added. The plates were again rocked for 1 h at room temperature, and washed three times with PBSTween after which 0.1 ml ofp-nitrophenyl phosphate at a concentration of 1 mg/ml in diethanolamine buffer (48) was dispensed into the wells. The plates were read at 405 nm after varying times (usually 10-60 min) in a Titertek multiscan photometer (Flow Laboratories, McLean, VA), which was standardized to wells containing all reactants except the experimental samples. Since color development was linear with time to an optical density of -2.0, the optical density change per minute was calculated. Where appropriate, these values were converted to nanograms per milliliter ofC3 by comparison with the standard curve. In all studies, another control included uncoated wells which received the reaction mixtures, conjugated antibody, and substrate. Where appropriate, these values were subtracted from experimental wells.
C3 Standard curve and conversion of ELISA values to nanograms ofC3b. A standard curve was included on each plate. Twofold dilutions ofpurified human C3 (10-300 ng/ml) in 0.1 ml volumes in PBS-Tween-EDTA-BSA were added in duplicate to wells that had been precoated with anti-C3. Precoating was accomplished by dessication of 0.1 ml volumes of a 5 jig/ml solution of anti-C3 in PBS overnight at room temperature. Enzyme-labeled anti-C3 and subsequently substrate were added exactly as described in the section above. A linear relationship between optical density at 405 nm and C3 concentration prevailed to a C3 concentration of 300-500 ng/ml.
Generalprocedurefor testing samplesfor the ELISA. Normal human serum (NHS), NHS containing 2.5 mM Mg and 10 mM EGTA (MgEGTA-NHS), complement component-deficient or depleted sera, or the PAP (in VBS) were incubated, generally in undiluted form, but occasionally in a dilution as specified in the text with an equal volume of a suspension of the activator in VBS. Generally, 50 Al volumes were used. Unless otherwise specified, E,, ER, neuraminidase-treated Es, and Raji cells were used at 1 X 108/ml; E. coli 04 and K pneumoniae at 1 X 109/ml; zymosan at 2.5 mg/ml; human immune complexes at 2.0 mg/ml; heparin at 500 U/ml; DNA at 20 Ag/ml; influenza virus at 1 X 1010 particles/ml; Epstein-Barr virus at 1 X 109 particles/ml; and Moloney leukemia virus at 2 mg/ml protein. The mixtures were incubated at 37°C and samples were taken at intervals. When dose-response rather than kinetic studies were carried out, equal volumes of MgEGTA-NHS and particles (from 1 X 106/ml to 1 X 109/ml) were incubated together for 40 min at 37°C. The samples of the reaction mixtures were diluted in PBS-Tween-EDTA-BSA and triplicate 0.1 ml samples were assayed in the ELISA. The dilution used for each activator was dependent on the potency or "strength" of the activator; for weak activators and thus bearing small amounts ofP and C3b, a 1:10 or 1:20 dilution was utilized, while for "strong" activators, a higher dilution such as 1:50 or 1:100 was used. Clinical sera were diluted 1:10 for assay.
Slight modifications were employed to assay the activation complex on the surface of the activator. These included washing after incubation of the activator with serum (erythrocytes) or centrifugation of 20-til aliquots of the reaction mixtures through a 300-,l layer of 20% sucrose in PBS with 10 mM EDTA (bacteria, zymosan). The pellets were resuspended in smaller (i.e., 0.3-0.5 ml) or larger (i.e., 1.0-1.5 ml) volumes of PBS-Tween-EDTA-BSA for weak or strong activators, respectively, and triplicate 0.1 ml samples were analyzed in the ELISA.
In some studies, supernatants of the activation mixtures were also tested. In these instances, samples of the reaction mixtures were diluted in PBS-Tween-EDTA-BSA and then centrifuged in the Beckman microfuge (Beckman Instruments, Inc., Fullerton, CA). Triplicate 0.1 ml samples of the supernatants were tested in the ELISA.
Binding ofPto C3b-coated erythrocytes. Equal volumes ofincreasing concentrations of activated P were incubated with EC3b (2.5 X 106/ml in VBS++) for 15 min at 370C. The cells were then washed, resuspended in VBS, and triplicate 0. l-ml samples were assayed in the ELISA.
Radiolabeled C3 deposition on activators. MgEGTA-NHS, to which radiolabeled C3 had been added, was incubated at 37°C in equal volumes with suspension of activators. At intervals, 20-Al samples were layered over 300 Al of 20% sucrose solution in VBS containing 10 mM EDTA. After centrifugation for 5 min in a Beckman microfuge, the tips of the tubes were amputated and the pellets and supernates and remainder of the tube counted in a Packard auto-gamma spectrometer (Packard Instrument Co., Inc., Downers Grove, IL). The radioactivity values were converted to molecules of C3 per activator particle by knowledge of the total C3 concentration of the radiolabeled C3 mixture (determined by Mancini analyses) and the specific radioactivity of the mixture. Duplicate samples of the same reaction mixtures were similarly centrifuged and the pellets analyzed in the ELISA as described above. Results C3 Standard Curve. As shown in Fig. 1 , the C3 standard curve yielded a linear relationship between the optical density and the C3 concentration to a level of 300-500 ng/ml. The lower limit of detection of C3 (Fig. 1 ) was 10-20 ng/ml (1-2 ng/well), a level which yielded an optical density of -0.100 after an hour of incubation. This amount of C3 corresponds approximately to the amount in a l0-' dilution of human serum (-16 ng/ml). Different C3 preparations yielded very similar standard curves (Fig. 1) . In other studies, serum samples of known C3 content yielded the same standard curve as purified C3 (not shown). The repetitive standard curves, which were included on each plate and encompassed several preparations of affinity-purified anti-P and enzyme-conjugated anti-C3, yielded only minor variations as noted in the next section. In contrast to many ELISA systems, direct coupling of the antigen to the plate yielded far lower sensitivity (Fig. 1) .
The ability ofthe anti-C3 employed in these studies to detect various forms and fragments of C3 was examined. For these experiments, purified C3, C3b, C3b dimers, C3bi, C3c, and C3d were substituted for C3 in the standard curve determination. The antibody detected C3, C3b, and C3b dimers with very similar dose-response characteristics. Slightly less reactivity was observed with C3bi and C3c (50-70% of that produced by C3) while the antibody detected C3d poorly (-10% of the optical density given by the same amount of C3).
Validity ofalternative pathway measurements by the ELISA. A number of different types of studies were carried out to ascertain the requirements for the ELISA and to show that it specifically measured C3b and P deposition mediated by activation of the alternative pathway. To show a requirement for both C3b and P on the same particle for reactivity in the ELISA, Figure 2 . Requirements for C3b and P on the same particle for reactivity in the ELISA. Varying amounts of activated P were incubated with EC3b. After washing, the cells were examined for ELISA reactivity.
E,-bearing C3b were reacted with varying amounts of activated P. After washing, the cells were examined in the ELISA. As shown in Fig. 2 , reactivity in the ELISA correlated with the amount of activated P added to the EC3b cells up to a plateau of reactivity at which point the cells are saturated with P.
Requirements for the proteins of the alternative pathway were also ascertained by adding an alternative pathway activator, E. coli 04, to normal serum, to serum depleted of C3, to serum depleted of C3 and reconstituted with physiological levels of purified C3, to serum depleted ofFactor B, and to serum depleted of Factor B and reconstituted with physiological levels of purified B. After incubation, the reaction mixtures were diluted and examined in the ELISA. E. coli added with serum depleted of C3 or Factor B failed to react in the ELISA (Fig. 3) . Reactivity was, however, regained after reconstitution of the missing component. In other studies, preneutralization of the anti-C3 conjugate or the anti-P coated plates with an excess of purified C3 or native P (EDTA serum), respectively, abrogated ELISA reactivity. Also, a serum-activator reaction mixture (E. coli 04) preincubated with an excess of anti-P before addition to the microtiter wells did not react in the ELISA (not shown).
The next series of studies were done to determine whether the integrity of the alternative activation pathway was required for reactivity in the ELISA. ER and zymosan were reacted with C2-deficient serum, MgEGTA-NHS, or normal human serum containing 20 mM EDTA (EDTA-NHS). As shown in Fig. 4 , normal serum, C2-deficient serum, and MgEGTA-NHS (thus lacking calcium required for the classical pathway) supported full ELISA reactivity with both activators, whereas EDTA-NHS (lacking also magnesium, needed for both pathways) did not. In comparable studies, C4-depleted serum and MgEGTA-NHS supported full reactivity with ER and with E. coli K. 12 (not shown). Similarly, C2-deficient serum and normal serum yielded comparable ELISA values after reaction with zymosan. EDTA invariably abrogated ELISA reactivity. Es, a nonactivator, failed to engender ELISA reactivity after incubation in serum.
In another approach, the effect oftreatment of E, with neuraminidase, a procedure known to convert E, into alternative pathway activators (42), was examined. Untreated and neuraminidase-treated Es were incubated with MgEGTA-NHS and periodic samples were layered over cushions of sucrose and centrifuged. The E, pellets were examined for ELISA reactivity.
The optical densities in the ELISA were converted to C3b molecules per cell by reference to the C3 standard curve. As shown in Fig. 5 ( Fig. 5) (Fig. 6) . Figure 6 . Comparison of the ELISA with measurements of radiolabeled C3b deposition. ER, K pneumoniae, and E, were incubated with MgEGTA-NHS containing radiolabeled C3. Samples taken at intervals were layered over sucrose cushions and centrifuged, and the pellets were assayed for radioactivity, and after resuspension, by the ELISA. Values were converted to C3b molecules per particle as described in the Methods. 24 h (not shown). Simultaneous C3 hemolytic measurements were also performed. At the 1-h time point, hemolytically active C3 in the serum had been depressed to 30% of the initial value; thereafter, C3 hemolytic activity declined with first order kinetics at a rate of -2.5%/h. In similar studies, serum incubated alone for several hours at 370C became reactive in the ELISA. Only a minor proportion of the serum C3 (0.007%) was involved in this spontaneous activation reaction at the time of maximal reactivity (6 h). After this time, reactivity was lost, with first order kinetics, at a rate of 1.25%/h. C3 he- molytic function in the spontaneously activated serum was lost with first order kinetics at a rate of 2.5%/h.
Measurement of activation kinetics with strong, moderate, and weak alternative pathway activators. Activation kinetics
were measured with ER, K. pneumoniae, Raji cells, and E,. The particles were incubated with MgEGTA-NHS and the mixtures sampled at intervals, diluted, and the aliquots examined in the ELISA. As shown in Fig. 9 , ER gave peak reactivity at 5-10 min, K. pneumoniae at 15-20 min, and Raji cells at >30 min.
ES were not reactive.
Applications and utility of the alternative pathway ELISA. The great sensitivity of the ELISA permits the study of very low levels of alternative pathway activation not readily quantitated by other techniques. For instance, the ELISA can be used to detect alternative pathway activation by particles as small as viruses (Table I) . In these studies, Epstein-Barr, Influenza, and Moloney leukemia viruses were incubated either with normal serum or with MgEGTA-NHS. After 20 min at 37°C, the mixtures were diluted and the aliquots examined in the ELISA. All three viruses activated the alternative pathway as shown by the generation of ELISA reactivity after incubation in MgEGTA-NHS (Table I) .
The ELISA can also be used to analyze reaction mechanisms of the alternative pathway. For example, in the present studies, we have observed ELISA reactivity engendered secondary to activation ofthe classical pathway by some, but not other classical pathway activators. For example, the nonimmune classical pathway activators, Moloney leukemia virus and DNA, triggered the amplification loop with P recruitment as manifested by reactivity in the ELISA after incubation in normal serum (Table  I) . Classical pathway activation leading to alternative pathway activation with P recruitment could also be demonstrated on adding zymosan Relationship between activator and time of peak reactivity in the ELISA. ER, K pneumoniae, and Raji cells were incubated with MgEGTA-NHS. Samples were taken at intervals and diluted, and the aliquots were examined in the ELISA: (-), ER; (0), K pneumoniae; (-), Raji cells, (U) E., the serum was first diluted to abrogate reactivity ofthe alternative pathway (Table I) . Other classical pathway activators such as EA, EAC4b3b, and heparin incubated with normal serum failed to recruit the alternative pathway (Table I) . Classical pathway reactivity by Moloney leukemia virus, DNA, zymosan, immune complexes, EA, and heparin, was independently verified in these studies. Detection of alternative pathway activation in clinical sera with the ELISA. The stability ofthe ELISA reactive complexes permits the ELISA to be used to examine clinical sera. Most ofthe modest numbers of sera tested from patients with ARDS, typhoid fever, and malaria were positive, with the ARDS patients exhibiting the highest levels (Fig. 10) . In contrast, nine sera from patients with C3NeF were not reactive in the alternative pathway ELISA (Fig. 10) . In other studies, 9 of 47 sera from patients with gram-negative sepsis, 6 of 25 sera from patients with acute trauma and shock, and sera from 3 of 29 patients with systemic lupus erythematosus (SLE) also showed elevated values in the alternative pathway ELISA.
Discussion
This paper describes and validates a new, specific, and highly sensitive ELISA for the detection and quantitation ofalternative complement pathway activation in human serum or plasma. Reactivity in the alternative pathway ELISA is dependent on the dual presence of P and a C3 derivative on the same activating particle or complex. In most cases, the derivative would be C3b, but C3bi,P would also be detected. Integrity of the alternative pathway and magnesium were required for ELISA reactivity (Fig. 2-4) . In a series of studies to validate the ELISA, E. were converted to alternative pathway activators by treatment with neuraminidase ( Fig. 5) , and the kinetics of alternative pathway In-101) n-5S
In-9) Figure 10 . activation assessed with the ELISA were identical to those observed in another technique used to measure activation, deposition of radiolabeled C3b (Fig. 6) . In other studies, MgEGTA-NHS and the PAP produced identical activation kinetics with several activators in the ELISA (Fig. 7) . Only modest differences in the detected numbers of bound C3b molecules were observed. The time of maximal reactivity detected by the ELISA correlated with the strength ofthe alternative pathway activator as assessed by an independent measure of activation, the restriction index (RI) (42) . The RI, which is the ratio of bound Factor H to bound C3b molecules, is an inverse measure ofactivator strength (42, 49, 50 (Fig. 10) . The ELISA should be readily adaptable to such use. The required antisera are available commercially, and affinity purification ofthe antisera could be accomplished without isolation of P and C3.
Studies with clinical sera showed that some of the sera from patients with typhoid fever and with malaria were moderately reactive in the alternative pathway ELISA while others were not (Fig. 10) . Parallel studies of the same samples by using the recently developed classical pathway ELISA (57) showed evidence of marked Cl activation in all ofthe typhoid fever samples and in several of the malaria samples. Most of the 10 sera from ARDS patients examined were quite reactive in the alternative pathway ELISA (Fig. 10) . In contrast, eight of these sera were negative, and two were only marginally reactive in the classical pathway ELISA. A proportion of sera from patients with gramnegative sepsis, trauma, and shock were also reactive in the alternative pathway ELISA. These findings with ARDS, gramnegative sepsis, trauma, and shock are in accord with indications of the involvement of the alternative pathway in these conditions (2, (14) (15) (16) (17) (18) .
26 of the 29 SLE sera examined here were negative in the alternative pathway ELISA. These sera all showed evidence of marked classical pathway activation (greatly reduced total hemolytic complement [CH50] levels), which is a common finding in this disease (58) (59) (60) . 3 of the 29 SLE sera did react in the alternative pathway ELISA; this confirmed the indications of activation of this pathway in the serum (61) (62) (63) and tissues (64, 65) of a proportion of patients with SLE. The relative contributions of the classical and alternative pathways to the pathogenesis and symptomatology of this disease are not understood.
Sera from patients with C3NeF in their circulation were not reactive in the alternative pathway ELISA. Such individuals have very low levels of circulating C3 due to marked and apparently continuous alternative pathway activation. The sera examined here also had extremely low C3 levels and absent alternative pathway functional activity. However, fluid-phase activation of the alternative pathway by C3NeF as manifested in clinical sera differs in certain respects from in vitro activation by zymosan, ER, gram-negative bacteria, and other activators. In particular, Factor B, P, and functional and protein C5 levels in sera containing C3NeF are generally normal (66) (67) (68) . The normal concentrations of Factor B and P indicate that there are relatively low levels of C3 convertase in the circulation of patients with C3NeF. The normal C5 levels document the absence of a C5 convertase in the circulation of patients with C3NeF; this is also a relevant observation as there is some evidence that P is recruited and activated by the C5 convertase (C3b)n, Bb (69) . While the explanations for these findings are not immediately apparent, they do account for the failure of such sera to react in the alternative pathway ELISA. Thus, sera from patients with certain, but not other diseases, are markedly reactive in the alternative pathway ELISA. It will be most interesting to examine sera from patients with a spectrum of diseases in which alternative pathway activation has been demonstrated or suspected to determine whether the test is a diagnostic aid and of value for monitoring clinical status and response to therapy. Since damaged tissues and cells, many gram-negative bacteria, virus-infected cells, and protozoa activate the alternative complement pathway in vitro, a comprehensive examination of sera from patients with burns, major trauma, surgical procedures, septicemia, shock syndromes and in particular septic shock, ARDS, and viral and tropical diseases will be of considerable interest.
